BeOne Medicines (formerly BeiGene) is projected to report Q2 2026 revenue of $1.61 billion and EPS of $1.59, with the current $316.01 share price trading well below the average analyst target of $404.60.
Investors are primarily focused on the global sales performance of the blockbuster BTK inhibitor BRUKINSA, which is expected to maintain its market-leading trajectory following successful expansion into frontline mantle cell lymphoma.
This earnings report is a key test of the company's operational leverage following its 2025 rebrand and redomiciliation to Switzerland. Analysts are also watching for sustained GAAP profitability and updates on the solid tumor pipeline, specifically the commercial uptake of TEVIMBRA in expanded indications.